{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:55:34Z","timestamp":1781333734500,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015638","name":"Japanese Breast Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The Japanese Breast Cancer Society initiated the breast cancer registry in 1975 and migrated the registry to the National Clinical Database-Breast Cancer Registry (NCD-BCR) in 2012. This annual report presents 2021 data on the NCD-BCR. We analyzed data from 98,540 breast cancer (BC) cases registered in 2021. In 2021, 99.4% of BC cases were females with a median age of 61. Most (57.5%) were diagnosed at early stages (Stage 0 or I). Breast-conserving surgery was performed in 42.8% of cases. Sentinel lymph node biopsy was performed in 67.8%, followed by radiotherapy in 71.0% of those post-conserving surgery. Regarding postoperative systemic therapy, 63.1% received endocrine therapy, 28.2% received chemotherapy, and 14.9% received molecular-targeted therapy. ER positivity was observed in 75.2%, HER2 in 13.6%, and Ki67 \u226530% in 29.1% of cases. The median age of premenopausal cases was 46 (interquartile range, 42\u201349) years and the median BMI was 21.5 (19.7\u201324.2) kg\/m<jats:sup>2<\/jats:sup> whereas the median age of postmenopausal cases was 69 (61\u201376) years and the median BMI was 23.0 (20.6\u201325.9) kg\/m<jats:sup>2<\/jats:sup>. In premenopausal cases, cases with normal BMI were more likely to be found at checkups without subjective symptoms and in the early stage than those with high BMI. The tendency of ER, PgR, HER2, and Ki67 status on BMI differed by menopause status; premenopausal cases with a lower BMI showed higher proportions of ER- and PgR-positive cancer and lower proportions of cancer with high Ki67. These nationwide descriptive statistics would help clinical explanation and further research on breast cancer.<\/jats:p>","DOI":"10.1007\/s12282-025-01698-3","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T18:37:11Z","timestamp":1745260631000},"page":"621-629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause status"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9538-4419","authenticated-orcid":false,"given":"Takaaki","family":"Konishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiraku","family":"Kumamaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Niikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Sanuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Tanakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Nagahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Sasada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kinukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehira","family":"Saji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Taira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"3","key":"1698_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12282-015-0599-6","volume":"22","author":"J Kurebayashi","year":"2015","unstructured":"Kurebayashi J, Miyoshi Y, Ishikawa T, Saji S, Sugie T, Suzuki T, et al. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the breast cancer registry of the japanese breast cancer society between 2004 and 2011. Breast Cancer. 2015;22(3):235\u201344.","journal-title":"Breast Cancer."},{"issue":"4","key":"1698_CR2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s12282-020-01081-4","volume":"27","author":"M Kubo","year":"2020","unstructured":"Kubo M, Kumamaru H, Isozumi U, Miyashita M, Nagahashi M, Kadoya T, et al. Annual report of the Japanese breast cancer society registry for 2016. Breast Cancer. 2020;27(4):511\u20138.","journal-title":"Breast Cancer."},{"issue":"2","key":"1698_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12282-022-01423-4","volume":"30","author":"K Tada","year":"2023","unstructured":"Tada K, Kumamaru H, Miyata H, Asaga S, Iijima K, Ogo E, et al. Characteristics of female breast cancer in Japan: annual report of the national clinical database in 2018. Breast Cancer. 2023;30(2):157\u201366.","journal-title":"Breast Cancer."},{"key":"1698_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-023-01526-6","author":"M Miyashita","year":"2023","unstructured":"Miyashita M, Kumamaru H, Niikura N, Sagara Y, Konishi T, Iwamoto T, et al. Annual report of the Japanese breast cancer registry for 2019. Breast Cancer. 2023. https:\/\/doi.org\/10.1007\/s12282-023-01526-6.","journal-title":"Breast Cancer"},{"issue":"5","key":"1698_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s12282-020-01139-3","volume":"27","author":"N Hayashi","year":"2020","unstructured":"Hayashi N, Kumamaru H, Isozumi U, Aogi K, Asaga S, Iijima K, et al. Annual report of the Japanese breast cancer registry for 2017. Breast Cancer. 2020;27(5):803\u20139.","journal-title":"Breast Cancer."},{"issue":"3","key":"1698_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-023-07022-x","volume":"201","author":"Y Adachi","year":"2023","unstructured":"Adachi Y, Asaga S, Kumamaru H, Kinugawa N, Sagara Y, Niikura N, et al. Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese national cancer database-breast cancer registry. Breast Cancer Res Treat. 2023;201(3):397\u2013408.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"1698_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12282-021-01307-z","volume":"29","author":"D Yotsumoto","year":"2022","unstructured":"Yotsumoto D, Sagara Y, Kumamaru H, Niikura N, Miyata H, Kanbayashi C, et al. Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the national breast cancer registry of Japan. Breast Cancer. 2022;29(1):1\u20138.","journal-title":"Breast Cancer."},{"key":"1698_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ejca.2021.06.006","volume":"154","author":"A Yamada","year":"2021","unstructured":"Yamada A, Kumamaru H, Shimizu C, Taira N, Nakayama K, Miyashita M, et al. Systemic therapy and prognosis of older patients with stage II\/III breast cancer: a large-scale analysis of the Japanese breast cancer registry. Eur J Cancer. 2021;154:157\u201366.","journal-title":"Eur J Cancer."},{"issue":"4","key":"1698_CR9","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s12282-022-01348-y","volume":"29","author":"M Terada","year":"2022","unstructured":"Terada M, Miyashita M, Kumamaru H, Miyata H, Tamura K, Yoshida M, et al. Surgical treatment trends and identification of primary breast tumors after surgery in occult breast cancer: a study based on the Japanese national clinical database\u2014breast cancer registry. Breast Cancer. 2022;29(4):698\u2013708.","journal-title":"Breast Cancer."},{"issue":"6","key":"1698_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s12282-022-01378-6","volume":"29","author":"A Shimomura","year":"2022","unstructured":"Shimomura A, Nagahashi M, Kumamaru H, Aogi K, Asaga S, Hayashi N, et al. Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan. Breast Cancer. 2022;29(6):985\u201392.","journal-title":"Breast Cancer."},{"issue":"3","key":"1698_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s10549-022-06749-3","volume":"196","author":"T Aihara","year":"2022","unstructured":"Aihara T, Kumamaru H, Ishitobi M, Miyashita M, Miyata H, Tamura K, et al. Prognosis and effectiveness of chemotherapy for medullary breast carcinoma. Breast Cancer Res Treat. 2022;196(3):635\u201345.","journal-title":"Breast Cancer Res Treat."},{"key":"1698_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2022.05.017","volume":"172","author":"A Yamada","year":"2022","unstructured":"Yamada A, Hayashi N, Kumamaru H, Nagahashi M, Usune S, Asaga S, et al. Prognostic impact of postoperative radiotherapy in patients with breast cancer and with pT1-2 and 1\u20133 lymph node metastases: a retrospective cohort study based on the Japanese breast cancer registry. Eur J Cancer. 2022;172:31\u201340.","journal-title":"Eur J Cancer."},{"issue":"2","key":"1698_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10549-020-05869-y","volume":"184","author":"R Ogiya","year":"2020","unstructured":"Ogiya R, Niikura N, Kumamaru H, Takeuchi Y, Okamura T, Kinoshita T, et al. Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study. Breast Cancer Res Treat. 2020;184(2):585\u201396.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"1698_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12282-019-00997-w","volume":"27","author":"T Hojo","year":"2020","unstructured":"Hojo T, Masuda N, Iwamoto T, Niikura N, Anan K, Aogi K, et al. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004\u20132009 data from the breast cancer registry of the Japanese breast cancer society. Breast Cancer. 2020;27(1):85\u201391.","journal-title":"Breast Cancer."},{"issue":"8","key":"1698_CR15","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1245\/s10434-019-07453-1","volume":"26","author":"M Miyashita","year":"2019","unstructured":"Miyashita M, Niikura N, Kumamaru H, Miyata H, Iwamoto T, Kawai M, et al. Role of postmastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer patients: a study from the Japanese breast cancer registry. Ann Surg Oncol. 2019;26(8):2475\u201385.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"1698_CR16","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10549-019-05413-7","volume":"178","author":"M Kubo","year":"2019","unstructured":"Kubo M, Kawai M, Kumamaru H, Miyata H, Tamura K, Yoshida M, et al. A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a national clinical database study. Breast Cancer Res Treat. 2019;178(3):647\u201356.","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"1698_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/annonc\/mdv611","volume":"27","author":"N Niikura","year":"2016","unstructured":"Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry. Ann Oncol. 2016;27(3):480\u20137.","journal-title":"Ann Oncol."},{"issue":"6","key":"1698_CR18","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/cam4.678","volume":"5","author":"M Kawai","year":"2016","unstructured":"Kawai M, Tomotaki A, Miyata H, Iwamoto T, Niikura N, Anan K, et al. Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese national clinical database\u2014breast cancer registry. Cancer Med. 2016;5(6):1328\u201340.","journal-title":"Cancer Med"},{"issue":"1","key":"1698_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10549-016-3984-8","volume":"160","author":"A Kataoka","year":"2016","unstructured":"Kataoka A, Iwamoto T, Tokunaga E, Tomotaki A, Kumamaru H, Miyata H, et al. Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese breast cancer registry. Breast Cancer Res Treat. 2016;160(1):163\u201372.","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"1698_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10549-016-3770-7","volume":"156","author":"T Iwamoto","year":"2016","unstructured":"Iwamoto T, Kumamaru H, Miyata H, Tomotaki A, Niikura N, Kawai M, et al. Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese breast cancer registry. Breast Cancer Res Treat. 2016;156(3):485\u201394.","journal-title":"Breast Cancer Res Treat."},{"issue":"5","key":"1698_CR21","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s12282-024-01604-3","volume":"31","author":"S Sasada","year":"2024","unstructured":"Sasada S, Kumamaru H, Hayashi N, Kinukawa N, Toi M, Jinno H, et al. Impact of immediate breast reconstruction on perioperative therapy: insights from a Japanese nationwide registry. Breast Cancer. 2024;31(5):909\u201316.","journal-title":"Breast Cancer."},{"issue":"35","key":"1698_CR22","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1200\/JCO.2016.68.4480","volume":"34","author":"S Jiralerspong","year":"2016","unstructured":"Jiralerspong S, Goodwin PJ. Obesity and breast cancer prognosis: evidence, challenges, and opportunities. J Clin Oncol. 2016;34(35):4203\u201316.","journal-title":"J Clin Oncol."},{"issue":"3","key":"1698_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12282-016-0673-8","volume":"23","author":"N Taira","year":"2016","unstructured":"Taira N, Arai M, Ikeda M, Iwasaki M, Okamura H, Takamatsu K, et al. The Japanese breast cancer society clinical practice guidelines for epidemiology and prevention of breast cancer 2015 edition. Breast Cancer. 2016;23(3):343\u201356.","journal-title":"Breast Cancer"},{"issue":"2","key":"1698_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10549-022-06638-9","volume":"194","author":"T Konishi","year":"2022","unstructured":"Konishi T, Fujiogi M, Michihata N, Matsui H, Tanabe M, Seto Y, et al. Association between body mass index and incidence of breast cancer in premenopausal women: a Japanese nationwide database study. Breast Cancer Res Treat. 2022;194(2):315\u201325.","journal-title":"Breast Cancer Res Treat."},{"issue":"11","key":"1698_CR25","doi-asserted-by":"publisher","first-page":"e181771","DOI":"10.1001\/jamaoncol.2018.1771","volume":"4","author":"MJ Schoemaker","year":"2018","unstructured":"The Premenopausal Breast Cancer Collaborative Group, Schoemaker MJ, Nichols HB, Wright LB, Brook MN, Jones ME, et al. Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol. 2018;4(11):e181771.","journal-title":"JAMA Oncol."},{"issue":"5","key":"1698_CR26","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/ijc.25744","volume":"129","author":"R Suzuki","year":"2011","unstructured":"Suzuki R, Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, et al. Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status\u2014the Japan public health center-based prospective study. Int J Cancer. 2011;129(5):1214\u201324.","journal-title":"Int J Cancer."}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01698-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-025-01698-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01698-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T12:44:53Z","timestamp":1750164293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-025-01698-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1698"],"URL":"https:\/\/doi.org\/10.1007\/s12282-025-01698-3","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HK and NK received collaborative research funding from Intuitive Surgical Sarl, Johnson and Johnson K.K., National Clinical Database, and Nipro corporation. NN received grants from Chugai, Daiichi Sankyo, Eisai, Mochida, Novartis, and Pfizer; and honoraria from Astra Zeneca, Chugai, Daiichi-Sankyo, Eli Lilly, MSD, and Pfizer. YS received honoraria from Astra Zeneca, Celltrion Healthcare Japan, Chugai, Daiichi Sankyo, Eisai, Eli Lily, Kyowa Kirin, MSD, Nippon Kayaku, Pfizer, and Sysmex. MM received honoraria from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, MSD, Pfizer, and Taiho. M Nagahashi received honoraria from AstraZeneca, Chugai, Daiichi Sankyo, Denka, Eli Lilly, Esai, Kyowa-Kirin, MSD, Novartis, Pfizer, and Taiho. MY received consulting fees from Roche Japan and honoraria from Agilent Technologies, Chugai Pharma, Daiichi Sankyo, MSD, Ono Yakuhin, and Roche Japan; and participated a board of Daiichi Sankyo. MK received research grants from Advalife Science, GL Sciences, Guardant Health AMEA, Kyowa Kirin, Nippon Kayaku, and Shimadzu; participated in the clinical trials of Eli Lilly, Japan Breast Cancer Research Group, Merck, and Roche; and received lecture fees from Chugai, Daiichi Sankyo, Devicor Medical Japan, Eisai, Guardant Health AMEA, Pfizer Japan, and Taiho. Sasada received grants from Chugai, Daiichi Sankyo, Eli Lilly, Gilead Sciences, and Nipro. S Saji received grants from Chugai, Daiichi Sankyo, Eisai, Taiho, and Takeda; participated in clinical trials of Astra Zeneca, Chugai, Daiichi Sankyo, Eli Lilly, Gilead, MSD, and Sanofi; received honoraria from Astra Zeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Exact Sciences, Gilead, Kyowa Kirin, MSD, Nipponkayaku, Novartis, Ono, Pfizer, Taiho, and Takeda; participated a board of Astra Zeneca, Chugai\/Roche, Daiichi Sankyo, Eli Lilly, Kyowa Kirin, MSD, and Pfizer; and was an executive board member of Breast International Group, Japan Breast Cancer Research Group, Japanese Breast Cancer Society, and Japanese Society of Medical Oncology. These conflicts of interest are outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}